Business Context and Reporting Period
Company: Cognition Therapeutics, Inc. (CGTX)
Filing Type: Form 8-K (Current Report)
Report Date: November 6, 2025
Reporting Period: Quarter ended September 30, 2025
Context: The Company, an emerging growth company incorporated in Delaware, filed this report to announce its financial results for the third quarter of 2025 via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text serves as a cover document referencing a press release (Exhibit 99.1) but does not contain specific financial data tables or figures within the body of this filing.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: Specific values for revenue, profit, cash flow, and liquidity are not present in the source text provided. Investors must refer to the attached Exhibit 99.1 (Press Release) for these details.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended September 30, 2025.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that management issued a press release on November 6, 2025, containing the results. No specific commentary, guidance, or outlook is included in the 8-K text itself.
Risks and Contingencies: No specific risks or contingencies are detailed in this document.
Unusual Items: None identified in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual financial figures (revenue, net loss, cash position) as they are not embedded in the 8-K text.
- Verify the Company's status as an Emerging Growth Company and any associated accounting election impacts.
- Confirm the trading symbol (CGTX) and exchange (Nasdaq) for accurate market data correlation.
- Check for any forward-looking statements or updated clinical trial timelines in the referenced press release, as this is a biopharmaceutical entity.